Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8GCG

MDM2 bound to inhibitor

This is a non-PDB format compatible entry.
Summary for 8GCG
Entry DOI10.2210/pdb8gcg/pdb
DescriptorE3 ubiquitin-protein ligase Mdm2, macrocyclic peptide inhibitor (3 entities in total)
Functional Keywordse3 ubiquitin-protein ligase, transferase, ligase, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight13781.67
Authors
Silvestri, A.P.,Muir, E.W.,Chakka, S.K.,Tripathi, S.M.,Rubin, S.M.,Pye, C.R.,Schwochert, J.A. (deposition date: 2023-03-01, release date: 2024-10-23)
Primary citationSilvestri, A.P.,Zhang, Q.,Ping, Y.,Muir, E.W.,Zhao, J.,Chakka, S.K.,Wang, G.,Bray, W.M.,Chen, W.,Fribourgh, J.L.,Tripathi, S.,He, Y.,Rubin, S.M.,Satz, A.L.,Pye, C.R.,Kuai, L.,Su, W.,Schwochert, J.A.
DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor.
Acs Med.Chem.Lett., 14:820-826, 2023
Cited by
PubMed Abstract: Synthetic macrocyclic peptides are an emerging molecular class for both targeting intracellular protein-protein interactions (PPIs) and providing an oral modality for drug targets typically addressed by biologics. Display technologies, such as mRNA and phage display, often yield peptides that are too large and too polar to achieve passive permeability or oral bioavailability without substantial off-platform medicinal chemistry. Herein, we use DNA-encoded cyclic peptide libraries to discover a neutral nonapeptide, UNP-6457, that inhibits MDM2-p53 interaction with an IC of 8.9 nM. X-ray structural analysis of the MDM2-UNP-6457 complex revealed mutual binding interactions and identified key ligand modification points which may be tuned to enhance its pharmacokinetic profile. These studies showcase how tailored DEL libraries can directly yield macrocyclic peptides benefiting from low MW, TPSA, and HBD/HBA counts that are capable of potently inhibiting therapeutically relevant protein-protein interactions.
PubMed: 37312849
DOI: 10.1021/acsmedchemlett.3c00117
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.47 Å)
Structure validation

238582

数据于2025-07-09公开中

PDB statisticsPDBj update infoContact PDBjnumon